This study will evaluate the effectiveness and safety of AMG 162 in treating women with Postmenopausal Osteoporosis.

Condition	Treatment or Intervention	Phase
Osteoporosis	Drug: AMG 162	Phase III

Ages Eligible for Study:  70 Years   -   90 Years,  Genders Eligible for Study:  Female

Criteria

Women who are 70 to 90 years of age may be eligible to participate.

Call Center      866-572-6436 

Alabama
      Research Site, Huntsville,  Alabama,  United States; Recruiting
Arizona
      Research Center, Tucson,  Arizona,  United States; Recruiting
      Research Site, Phoenix,  Arizona,  United States; Recruiting
California
      Research Site, Upland,  California,  United States; Recruiting
      Research Site, Fresno,  California,  United States; Recruiting
      Research Site, Laguna Hills,  California,  United States; Recruiting
      Research Center, Eureka,  California,  United States; Recruiting
      Research Center, San Diego,  California,  United States; Recruiting
Colorado
      Research Site, Lakewood,  Colorado,  United States; Recruiting
      Research Site, Boulder,  Colorado,  United States; Recruiting
Florida
      Research Site, Lake Worth,  Florida,  United States; Recruiting
      Research Site, Leesburg,  Florida,  United States; Recruiting
      Research Site, Palm Springs,  Florida,  United States; Recruiting
      Research Site, Stuart,  Florida,  United States; Recruiting
      Research Center, Delray Beach,  Florida,  United States; Recruiting
      Research Site, Clearwater,  Florida,  United States; Recruiting
      Research Site, Largo,  Florida,  United States; Recruiting
      Research Site, Sarasota,  Florida,  United States; Recruiting
Georgia
      Research Site, Decatur,  Georgia,  United States; Recruiting
      Research Site, Gainesville,  Georgia,  United States; Recruiting
Hawaii
      Research Site, Honolulu,  Hawaii,  United States; Recruiting
Idaho
      Research Site, Meridian,  Idaho,  United States; Recruiting
Illinois
      Research Site, Springfield,  Illinois,  United States; Recruiting
Indiana
      Research Site, Indianapolis,  Indiana,  United States; Recruiting
      Research Site, Newburgh,  Indiana,  United States; Recruiting
Kansas
      Research Site, Kansas City,  Kansas,  United States; Recruiting
Maryland
      Research Site, Laurel,  Maryland,  United States; Recruiting
      Research Site, Bethesda,  Maryland,  United States; Recruiting
Nebraska
      Research Site, Omaha,  Nebraska,  United States; Recruiting
New Jersey
      Research Site, Berlin,  New Jersey,  United States; Recruiting
New Mexico
      Research Site, Albuquerque,  New Mexico,  United States; Recruiting
Oregon
      Research Site, Portland,  Oregon,  United States; Recruiting
Pennsylvania
      Research Site, Pittsburgh,  Pennsylvania,  United States; Recruiting
      Research Site, Duncansville,  Pennsylvania,  United States; Recruiting
South Carolina
      Research Site, Anderson,  South Carolina,  United States; Recruiting
Texas
      Research Site, Dallas,  Texas,  United States; Recruiting
      Research Center, Corsicana,  Texas,  United States; Recruiting
Washington
      Research Site, Lakewood,  Washington,  United States; Recruiting

Study ID Numbers:  20030216
Record last reviewed:  April 2005
Last Updated:  April 1, 2005
Record first received:  August 13, 2004
ClinicalTrials.gov Identifier:  NCT00089791
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08